We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Icon reports second quarter 2013 revenue of $334 million

Icon reports second quarter 2013 revenue of $334 million

July 26, 2013
CenterWatch Staff

CRO Icon said net revenues grew 21% to $334.2 million in the second quarter ended June 30, from $277 million in the year-ago quarter. Revenue in the first half of 2013 rose 23% to $651 million, from $529 million a year ago.

Income from operations in the first half of 2013 was $58.3 million, or 9% of revenue, compared with $28.4 million or 5.4% of revenue in the first half of 2012. Income from operations was $30.9 million, or 9.3% of revenue, compared to $16.6 million, or 6% of revenue, in the year-ago quarter. Net income was $26.5 million, up from $12.9 million a year ago. Net income for the first half of 2013 was $48.7 million, compared with $21.9 million in 2012.

Guidance for 2013 has been updated, with revenue expected to be in the range of $1.3 billion to $1.32 billion, and earnings-per-share in the $1.54 to $1.64 range.

Cash generated from operating activities was $10.8 million, after expenditure of $26 million on prior period acquisition earn outs and capital expenditure of $7.8 million. The company’s net cash amounted to $184 million at the end of the second quarter, compared to net cash of $190 million on Dec. 31, 2012. 

During the quarter, the company recorded a charge of $4.6 million for various restructuring costs. U.S. GAAP income from operations after these items amounted to $26 million, or 7.9% of revenue. U.S. GAAP net income for the quarter was $22 million, or 36 cents per share.

Global News CROs/Service Providers

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing